Drug Trial Radar · NCT07281274
ADO-5030 in Bronchoconstriction Challenge, Phase 1b
Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Jun 1, 2026
Study completion Jul 1, 2026
Sponsor
- Lead sponsor
- AdovateIndustry
- Sponsor type
- Industry
- Collaborators
- University of Virginia
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 study to learn about the safety and pharmacokinetics of the study drug in patients with asthma and whether the study drug has effect during a respiratory challenge.
Conditions
- Asthma (Diagnosis)
Interventions
ADO-5030Drug
Single oral dose of ADO-5030.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in PC20 AMP.Time frame: As this is a single dose trial, the timeframe is the duration in which PC20 AMP is reached during the AMP Challenge with ADO-5030 on Day 1.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Virginia
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.